

**H2020 LIBRA Workshop:
Sex & Gender in Research & Experimental Design**
Babraham Institute, Cambridge, UK
26-27th Sept 2018



Draft programme

Day 1 – 2pm start

Welcome and introduction to LIBRA by Project Coordinator **Isabelle Vernos**, Research Professor CRG, Barcelona, ERC Scientific Council Member, LIBRA Coordinator (confirmed)

Outlining the challenge – **Sabine Oertelt-Prigione**, Professor of Gender in Primary and Transmural Care, Radboud University, Nijmegen (confirmed)

How this contributes to the reproducibility crisis – **Natasha Karp**, Senior Research Statistician, AstraZeneca, Cambridge (confirmed)

Tea/coffee

Chair: **Jim Smith**, Director of Science, Wellcome Trust, London (confirmed)

Funder that already includes the requirement to address gender in grant proposals – **Peter Brown**, Director of the Irish Research Council, Dublin (confirmed)

- Why have they done this?
- How have they done this?
- What response have they had from the research community? From other funders?
- How do they evaluate the sex/gender experimental aspect of proposals
- How has it changed the science that they fund?
- What science has come about as a result of this? Or is it too early?
- How does it impact on the cost of grants?
- Are they allowing additional costs to accommodate additional experimental work?

Publishers' role in addressing the sex/gender dimension of the research – **Stephane Berghmans**, Vice president of Academic Relations EU at Elsevier (invited)

- Is this an area where publishers/journals can help promote good practice?
- If they require the issue to be addressed, why and how have they done this? Or why have they not done this?
- What response have they had from the research community? From other publishers?
- How do/would they evaluate the sex/gender experimental aspect of papers? Are/would reviewers be required to comment?
- How would it change the science that they publish?

Panel discussion

Dinner & Accommodation at Downing College, Cambridge

Day 2

Chair: **Mene Pangalos**, Executive Vice President, AstraZeneca, Cambridge (confirmed)

Leading and Innovative measures to achieve **B**alance in **R**esearch **A**ctivities

Industry – **Paul-Peter Tak**, Senior Vice President of R&D, GSK, Stevenage (confirmed)

- What is their perspective?
- They rely on academic research outcomes – is the lack of consideration of sex/gender a problem?
- Will it ultimately be cost-effective to address this at early stages of research?
- What is the plan from industry to address this?

Routes to Government – **Ana Puy**, Spanish Ministry of Science and Innovation (confirmed)

- Lessons from GENDER-NET
- How do we engage governments?

Tea/coffee

Chair: to be decided

Panel discussion

Science & gender case studies: **Wilbert Zwart**, Group Leader, NKI (confirmed); **Irene Miguel-Aliaga**, Professor, Imperial College, London (confirmed)

Conclusions and next steps followed by lunch

Additional confirmed organisations

Cancer Research UK, ScienceEurope, German Research Foundation, Swedish Research Council, Swiss National Science Foundation (SNSF), NC3Rs, AAAS Science International, Advance HE (Athena SWAN Charter), UK Home Office, Sanita Italian Funding Agency, Dutch Cancer Society (KWF), Technology Agency of the Czech Republic, MedImmune, Biotechnological and Biological Sciences Research Council (BBSRC, UK)

LIBRA is a Coordination & Support Action project of the European Commission's framework programme for Research and Innovation Horizon 2020 (665937).